首页 > 市场调查报告书 > 医疗设备

测量仪器生技设备

市场调查报告书

商品编码

1629841

全球液相层析质谱市场 - 2024-2031

Global Liquid Chromatography Mass Spectrometry Market - 2024-2031

出版日期: 2024年12月30日 | 出版商:

DataM Intelligence | 英文 205 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年全球液相层析质谱市场规模达63.5亿美元，预计2031年将达178.8亿美元，2024-2031年预测期间复合年增长率为13.81%。

由于多个领域（尤其是医疗保健和製药领域）研发 (R&D) 支出的增加，预计液相层析质谱 (LC-MS) 市场将大幅成长。对复杂分析方法的需求不断增长，特别是在环境监测和个人化医疗领域，进一步增强了市场。

LC-MS 技术的持续发展，包括解析度、灵敏度和速度的提高，正在增强这些系统的整体性能和功能，促进其广泛实施。技术进步，包括高解析度和混合质谱仪的出现，对于市场的成长至关重要。这些进步增强了分析能力，并促进更快、更精确的结果。

此外，自动化和资料处理软体与 LC-MS 系统的整合显着提高了工作流程效率和分析吞吐量。安捷伦科技公司的 Ultivo 三重四极桿 LC/MS 系统于 2022 年 1 月推出，展示了复杂的系统如何满足许多应用对提高灵敏度和稳健性日益增长的需求，从而推动市场扩张。

此外，製药和生技产业不断增加的研发投资是 LC-MS 产业的重要催化剂。製药公司在全球研发支出中占有很大份额，特别是在生物製药和个人化医疗方面，预计药物发现、开发和临床试验中对质谱解决方案的需求将会增加。

动力学

製药和生物技术的进步

随着各行业对新药发现和开发方法的需求不断增加，LC-MS 系统的部署变得至关重要。 LC-MS 技术有助于对复杂生物基质中的多种物质进行准确识别和定量，显着提高研究效率并促进创新发现。对 LC-MS 技术的日益依赖正在促进药物开发的进步，从而有助于市场的成长。

製药和生物技术产业研发 (R&D) 支出的大幅成长正在推动对质谱的需求。製药公司在生物製药、个人化医疗和其他先进治疗领域的投资导致研发活动显着增加。

这些业务占全球研发支出的很大一部分，根据 2022 年欧盟工业研发投资记分牌，占 21.5%，从而促进了从发现到临床试验的整个药物开发过程中质谱分析的使用。因此，预计这种不断增加的投资将在未来几年推动 LC-MS 市场的持续成长。

食品和安全问题日益严重

人们对食品安全意识的不断增强和严格的全球法规正在推动液相层析-质谱法 (LC-MS) 等现代分析方法的使用。该技术对于透过准确检测和量化污染物和添加剂来确保遵守食品安全法规至关重要。

LC-MS 非常擅长检测复杂的化学污染物混合物，为筛选、确认和定量提供无与伦比的灵敏度和选择性。该技术解决食品真实性、营养评估和标籤精度等基本问题的能力使其成为先进食品检测领域的基本要素。

食品标籤错误、微生物污染和食源性疾病的发生率越来越高，因此严格检测程序的必要性越来越高。三重四极桿 (QqQ) 和飞行时间 (TOF) 技术等串联质谱技术的进步改进了 LC-MS 系统的功能，使其对于遵守法规和增强消费者信心至关重要。

成本高

液相层析质谱 (LC-MS) 系统的高成本是产业扩张的一个相当大的障碍，特别是在财务限制限制使用复杂分析仪器的新兴地区。设备的初始资本投资以及持续的维护和营运成本经常阻碍小型实验室和研究组织实施 LC-MS 技术。这限制了这些技术的采用率，阻碍了整体市场的成长。

此外，与 LC-MS 相关的大量营运费用（包括消耗品、试剂和专业人员培训）加剧了公司的财务压力。因此，许多潜在客户可能会选择更经济的选择，例如传统的色谱方法或质谱系统，其初始成本较低，但与 LC-MS 相比可能在精度和灵敏度方面存在缺陷。价格敏感度限制了 LC-MS 产业的成长潜力，特别是在学术界和小型公司等预算敏感的产业。

The Liquid Chromatography Mass Spectrometry (LC-MS) market is projected to undergo substantial growth due to heightened spending in research and development (R&D) across multiple sectors, especially in healthcare and pharmaceuticals. The increasing demand for sophisticated analytical methods, especially in environmental monitoring and personalized medicine, further strengthens the market.

The ongoing developments in LC-MS technology, including enhanced resolution, sensitivity and speed, are augmenting the overall performance and capabilities of these systems, facilitating their broad implementation. Technological advancements, including the emergence of high-resolution and hybrid mass spectrometers, are crucial to the market's growth. The advances enhance analytical capabilities and facilitate swifter and more precise outcomes.

Furthermore, the integration of automation and data processing software with LC-MS systems has markedly enhanced workflow efficiency and analytical throughput. The launch of Agilent Technologies' Ultivo Triple Quadrupole LC/MS system in January 2022 illustrates how sophisticated systems can satisfy the increasing demand for improved sensitivity and robustness across many applications, hence propelling market expansion.

Moreover, the increasing investments in research and development within the pharmaceutical and biotechnology industries are essential catalysts for the LC-MS industry. Pharmaceutical businesses represent a substantial share of global R&D spending, especially in biopharmaceuticals and personalized medicine, leading to an anticipated rise in the need for mass spectrometry solutions in drug discovery, development and clinical trials.

Dynamics

Advancements in Pharmaceutical and Biotechnology

The deployment of LC-MS systems is becoming essential, with the increasing demand for new drug discovery and development methods in various industries. LC-MS technology facilitates the accurate identification and quantification of diverse substances in intricate biological matrices, markedly enhancing research efficiency and fostering innovative discoveries. The increased dependence on LC-MS technologies is facilitating advancements in medication development, hence aiding market growth.

The significant rise in research and development (R&D) spending in the pharmaceutical and biotechnology industries is driving the demand for mass spectrometry. Investments by pharmaceutical corporations in biopharmaceuticals, personalized medicine and other advanced therapeutic domains have resulted in a notable increase in research and development activity.

These businesses represent a significant share of global R&D expenditure, including 21.5% as per the 2022 EU Industrial R&D Investment Scoreboard, thereby facilitating the use of mass spectrometry throughout the drug development process, from discovery to clinical trials. Thus, this increasing investment is anticipated to propel the ongoing growth of the LC-MS market in the forthcoming years.

Rising Food and Safety Concerns

The increasing awareness of food safety and stringent global regulations are propelling the utilization of modern analytical methods like Liquid Chromatography-Mass Spectrometry (LC-MS). This technology is essential for guaranteeing adherence to food safety regulations through accurate detection and quantification of pollutants and additives.

LC-MS is exceptionally proficient at detecting intricate mixtures of chemical pollutants, providing unmatched sensitivity and selectivity for screening, confirmation and quantification. The technology's capacity to tackle essential issues including food authenticity, nutritional evaluation and labeling precision has established it as a fundamental element in the advancing food testing domain.

The increasing occurrences of food mislabeling, microbial contamination and foodborne illnesses have heightened the necessity for rigorous testing procedures. Advancements in tandem mass spectrometry, such as triple quadrupole (QqQ) and time-of-flight (TOF) technologies, have improved the functionality of LC-MS systems, rendering them essential for regulatory adherence and consumer confidence.

High Cost

The high cost of Liquid Chromatography Mass Spectrometry (LC-MS) systems is a considerable obstacle to industry expansion, especially in emerging regions where financial limitations restrict access to sophisticated analytical instruments. The initial capital investment for the equipment, together with the continuous maintenance and operational costs, frequently dissuades smaller laboratories and research organizations from implementing LC-MS technology. This limits the adoption rate of these technologies, obstructing total market growth.

Moreover, the substantial operating expenses linked to LC-MS, encompassing consumables, reagents and specialist personnel training, exacerbate the financial strain on companies. Consequently, numerous prospective customers may choose more economical options, such as conventional chromatographic methods or mass spectrometric systems, which present reduced initial costs but may be deficient in precision and sensitivity compared to LC-MS. The price sensitivity constrains the growth potential of the LC-MS industry, particularly in budget-conscious sectors such as academics and small-scale companies.

Segment Analysis

The global liquid chromatography mass spectrometry market is segmented based on technology, application, end-user and region.

Revolutionizing Drug Development with LC-MS

LC-MS is essential for assessing medicines throughout different phases of the drug development lifecycle. From the preliminary phases of drug development, where it facilitates the separation and characterisation of prospective drug candidates from synthetic or natural substances, to sophisticated metabolism investigations (both in vitro and in vivo), LC-MS guarantees precise and dependable analytical outcomes.

Furthermore, LC-MS is crucial for detecting contaminants and degradation products, so guaranteeing the safety and efficacy of pharmaceutical formulations. Its capacity to identify and measure intricate molecular structures with exceptional sensitivity and specificity renders it an essential instrument for pharmaceutical research. The strong applicability of LC-MS systems in drug discovery and development enhances their demand, establishing them as essential tools in the pharmaceutical sector.

Geographical Penetration

Regulatory Support and Sustainable Urban Mobility in Europe

The North American Liquid Chromatography Mass Spectrometry (LCMS) market is witnessing significant growth, propelled by the swift advancement of the pharmaceutical sector and heightened spending in research and development (R&D). The region gains advantages from the involvement of prominent entities like Thermo Fisher Scientific, Agilent Technologies and Bio-Rad Laboratories, whose discoveries and commercial endeavors substantially contribute to promoting adoption. The demand for clinical diagnostic applications, along with heightened scientific understanding and the presence of competent professionals, further augments the use of LCMS systems.

Programs such as Clarivate Analytics' Life Science Alliances Program, which supports drug and medical device developers in enhancing research and development as well as commercialization, are anticipated to increase the need for LCMS systems. Moreover, the region's rising R&D investment highlights its potential for market expansion. US biopharmaceutical sector has allocated almost US$ 90 billion to R&D endeavors, underscoring the substantial prospects for LCMS applications in drug discovery, diagnostics and other advanced research domains.

Competitive Landscape

The major global players in the market include Danaher Corporation, PerkinElmer, Inc., Waters Corporation, Bruker Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Shimadzu Corporation, JEOL Ltd. and Newomics, Inc. and LECO Corporation.

Sustainability Analysis

The LC-MS (Liquid Chromatography-Mass Spectrometry) market is progressively conforming to the tenets of green chemistry, emphasizing the reduction of environmental effect while improving laboratory efficiency. Green chemistry promotes the utilization of eco-friendly reaction medium, the reduction of hazardous chemical waste and the optimization of laboratory procedures to decrease energy usage. Liquid chromatography, a prevalent analytical technique in pharmaceuticals, biotechnology and environmental monitoring, has considerable opportunities for the incorporation of sustainable practices.

The implementation of environmentally friendly technologies is essential for promoting sustainability in the LC-MS sector. Contemporary chromatography apparatus has improved in energy efficiency and the adoption of methods like solvent recycling and waste reutilization further promotes sustainability. Furthermore, the utilization of supercritical CO2 and alternative green solvents offers a promising strategy for minimizing the environmental impact of the approach.

Suppliers such as Scientific Laboratory Supplies (SLS) and Merck are facilitating the transition by offering environmentally sustainable solutions that promote green chemistry in laboratories. As the industry increasingly prioritizes sustainability, these initiatives are crucial for transforming LC-MS into both a potent analytical instrument and a more environmentally responsible option.

Technological Advancement

The LC-MS market is experiencing substantial technological developments, propelled by innovations in low-flow LC-MS applications and the integration of cutting-edge technology. The shift of nano-, capillary- and micro-flow LC-MS from research and development laboratories to widespread industrial use has transformed analytical processes, especially in proteomics and drug discovery.

Innovations such as ion mobility spectrometry (IMS) augment molecular characterisation by providing an extra dimension of separation, hence enhancing specificity and analytical peak capacity for intricate materials. The developments, along with efforts to enhance time-of-flight detection, are establishing new benchmarks for precision and resolution in biomolecular analysis.

Manufacturers are prioritizing sustainability by adopting environmentally friendly methods that line with global development objectives. Advanced systems, such as SCIEX's QTOF instruments, enhance speed and sensitivity while integrating novel capabilities like SWATH collection and EAD fragmentation for thorough compound analysis.

Innovative integrations, such as icIEF-UV/MS and CE-ESI, significantly improve sensitivity and quantification for biotherapeutic applications while minimizing ion suppression. These technical advancements are transforming the capabilities of LC-MS systems, ensuring they fulfill the evolving requirements of the pharmaceutical and biopharmaceutical sectors with accuracy, efficiency and environmental awareness.

By Technology

Time of Flight
Quadrupole - Time of Flight
Hybrid LC-MS
Ion Trap LC-MS
Others

By Application

Drug Discovery and Development
Clinical Diagnostics
Environmental Testing
Forensic Testing
Pharmaceutical and Biotechnology
Others

By End-User

Academic Research Institutions
Contract Research Organizations
Biopharmaceutical Companies
Hospitals and Diagnostic Centers
Pathology Laboratories
Forensic Laboratories
Others

By Region

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
South America
- Brazil
- Argentina
- Rest of South America
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Middle East and Africa

Key Developments

In June 2024, Thermo Fisher Scientific Inc. introduced the Thermo Scientific Stellar Mass Spectrometer (MS), a novel solution aimed at advancing translational omics research. This sophisticated instrument provides rapid throughput, elevated sensitivity and intuitive operation, facilitating researchers in achieving revolutionary findings with greater efficiency.
In April 2024, Waters Corporation launched the Alliance iS Bio HPLC System, aimed at addressing the operational and analytical issues encountered by biopharma quality control laboratories. This cutting-edge HPLC system combines sophisticated bio-separation technology with integrated instrument intelligence capabilities, designed to improve efficiency for biopharma quality control analysts. This approach enables users to potentially decrease common errors by up to 40%, therefore reducing the time allocated to addressing issues associated with failed runs and out-of-specification outcomes.

Why Purchase the Report?

To visualize the global liquid chromatography mass spectrometry market segmentation based on technology, application, end-user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the liquid chromatography mass spectrometry market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global liquid chromatography mass spectrometry market report would provide approximately 62 tables, 61 figures and 205 pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Technology
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Advancements in Pharmaceutical and Biotechnology
  - 4.1.1.2. Rising Food and Safety Concerns
- 4.1.2. Restraints
  - 4.1.2.1. High Cost
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion

6. By Technology

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 6.1.2. Market Attractiveness Index, By Technology
6.2. Time of Flight*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Quadrupole - Time of Flight
6.4. Hybrid LC-MS
6.5. Ion Trap LC-MS
6.6. Others

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Drug Discovery and Development*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Clinical Diagnostics
7.4. Environmental Testing
7.5. Forensic Testing
7.6. Pharmaceutical and Biotechnology
7.7. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Academic Research Institutions*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Contract Research Organizations
8.4. Biopharmaceutical Companies
8.5. Hospitals and Diagnostic Centers
8.6. Pathology Laboratories
8.7. Forensic Laboratories
8.8. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. US
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. UK
  - 9.3.6.3. France
  - 9.3.6.4. Italy
  - 9.3.6.5. Spain
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. Australia
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Danaher Corporation*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. PerkinElmer, Inc.
11.3. Waters Corporation
11.4. Bruker Corporation
11.5. Thermo Fisher Scientific Inc.
11.6. Agilent Technologies, Inc.
11.7. Shimadzu Corporation
11.8. JEOL Ltd.
11.9. Newomics, Inc.
11.10. LECO Corporation

LIST NOT EXHAUSTIVE